| Biomarker ID | 1284 |
| PMID | 24391718 |
| Year | 2013 |
| Biomarker | PDCD6IP; EEF1A2; FASN; VPS28; PABPC1;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; YWHAE; SLC3A2; ARF1; CXADR; EHD4; HSP90AB2P; HSP90AB3P; IQGAP1; KRT9; KRT2; MFGE8; PARK7; PGK1; PRDX1; RAB10; RAB1A;RAP1A; AHCY; TUBA1A; CCT5; UGDH; |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): [] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PC346C vs PNT2C2 |
| Type of Biomarker | Diagnostic |
| Cohort | 2 immortalized primary prostate epithelial cells (PNT2C2 and RWPE- 1) and 2 PCa cell lines (PC346C and VCaP) were chosen for this study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Selected Genes validated on cell lines by Western Blotting |
| Technical Name | PDCD6IP, EEF1A2, FASN, VPS28, PABPC1, YWHAB, ANXA2, ATP1A1, ATP1B1, ATP1B3, BSG, CLIC1, ITGA6, F11R, ACTA2, ATP12A, CTNNB1, ENO1, HSPA5, KPNB1, PKM2, TPI1, YWHAE, SLC3A2, ARF1, CXADR, EHD4, HSP90AB2P, HSP90AB3P, IQGAP1, KRT9, KRT2, MFGE8, PARK7, PGK1, PRDX1, RAB10, RAB1A, RAP1A, AHCY, TUBA1A, CCT5, UGDH |